Document is current
Any future updates will be listed below
-
Authors
Ju, Cheng-Wei https://orcid.org/0000-0002-2250-8548
Lyu, Ruitu https://orcid.org/0000-0003-4597-1604
Li, Han
Wei, Jiangbo https://orcid.org/0000-0003-2691-6490
Parra Vitela, Alberto J. https://orcid.org/0000-0001-6204-7443
Dougherty, Urszula
Kwesi, Akushika
Luna, Alexander
Zhu, Xuanhao
Shen, Shenghai
Liu, Yunzheng
Wang, Liangliang
Cui, Xiaolong
Xu, Yuzhi
Jiang, Bochen https://orcid.org/0000-0001-6686-8847
Ji, Yiyi https://orcid.org/0000-0001-5598-0059
Xia, Peng
West-Szymanski, Diana C.
Sun, Chenxi https://orcid.org/0009-0000-7849-976X
Zhong, Yuhao
Ye, Chang https://orcid.org/0000-0003-0236-5671
Moran, Angelica https://orcid.org/0000-0003-4013-2182
Lehmann, Christopher
Pamer, Eric https://orcid.org/0000-0002-6755-9904
Zhang, Wei https://orcid.org/0000-0003-0875-263X
Bissonnette, Marc https://orcid.org/0000-0001-8420-4294
Zhang, Li-Sheng https://orcid.org/0000-0003-1872-9978
He, Chuan https://orcid.org/0000-0003-4319-7424
- License Information
-
More Information
Article History
Received: 17 April 2024
Accepted: 5 June 2025
First Online: 8 July 2025
Competing interests
: A patent application for LIME-seq and cfRNA modification as biomarkers has been filed by the University of Chicago. C.H. is a scientific founder, member of the scientific advisory board and equity holder of Aferna Bio, Ellis Bio and AllyRNA, a scientific cofounder and equity holder of Accent Therapeutics and a member of the scientific advisory board of Rona Therapeutics. The remaining authors declare no competing interests.
